Dr. Shihong Wei 魏世鸿
Chief Physician
Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation and comprehensive treatment for thoracic tumors, including lung cancer, breast cancer, esophageal cancer, and mediastinal tumors. Expertise in diagnosis, differential diagnosis, and radiation techniques such as IMRT, IGRT, and SBRT.
Dr. Wei graduated from Lanzhou Medical College in 2000 and earned a master’s degree in 2007. Training includes the Radiation Oncology Department at Shanghai Cancer Hospital and the Curie Institute in France. A key member of the Lanzhou heavy ion therapy team, Dr. Wei has published over 10 papers, authored one monograph on breast cancer radiation therapy, and contributed to three other books.
Professional roles
- Standing Committee Member, Chinese Medical Association (Gansu Branch)
- Chair, Small Cell Lung Cancer Professional Committee, Gansu Anti-Cancer Association
- Director, Gansu Provincial Tumor Radiation Therapy Quality Control Center
Name order: in Chinese the family name comes first (Wei Shihong). Papers usually list the name as Shihong Wei or Wei S.
Selected publications
19 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2025 (senior author): Meta-analysis of the efficacy and safety of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy. PubMed 40980147
- Oncol Lett, 2025 (senior author): Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review). PubMed 40799300
- Panminerva Med, 2024 (senior author): Risk prediction of radioactive lung injury in patients with small cell lung cancer based on peripheral blood lymphocyte subsets. PubMed 38093627
- Front Oncol, 2022 (senior author): An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. PubMed 35978809
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion